Trial
NCT02418000
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Spirita Oncology, LLC
Collaborators
—
Condition
AML
Intervention
E6201
Why stopped
Insufficient efficacy in Phase 1 dose-escalation portion of study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-20